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Abstract
Background: Vaginitis is a common complaint in primary care. In uncomplicated candidal vaginitis, there are no
differences in effectiveness between oral or vaginal treatment. Some studies describe that the preferred treatment
is the oral one, but a Cochrane’s review points out inconsistencies associated with the report of the preferred way
that limit the use of such data. Risk factors associated with recurrent vulvovaginal candidiasis still remain
controversial.
Methods/Design: This work describes a protocol of a multicentric prospective observational study with one year
follow up, to describe the women’s reasons and preferences to choose the way of administration (oral vs topical)
in the treatment of not complicated candidal vaginitis. The number of women required is 765, they are chosen by
consecutive sampling. All of whom are aged 16 and over with vaginal discharge and/or vaginal pruritus, diagnosed
with not complicated vulvovaginitis in Primary Care in Madrid.
The main outcome variable is the preferences of the patients in treatment choice; secondary outcome variables are
time to symptoms relief and adverse reactions and the frequency of recurrent vulvovaginitis and the risk factors. In
the statistical analysis, for the main objective will be descriptive for each of the variables, bivariant analysis and
multivariate analysis (logistic regression). The dependent variable being the type of treatment chosen (oral or
topical) and the independent, the variables that after bivariant analysis, have been associated to the treatment
preference.
Discussion: Clinical decisions, recommendations, and practice guidelines must not only attend to the best
available evidence, but also to the values and preferences of the informed patient.
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Vaginitis is the most frequent reason for gynecology
consultation in primary health care services. It is esti-
m a t e dt h a t7 5 %o fw o m e ne x p e r i e n c ea tl e a s to n ee p i -
sode of vulvovaginal candidiasis throughout her life and
40-50% of them have at least one recurrence [1].
The most frequent cause of vulvovaginal inflammation
is infective, beeing the main organisms: Gardnerella
vaginalis (15-50%), Candida (C) (20-25%) and Tricho-
monas vaginalis (5-50%) species, with a frequency distri-
bution that depends on the populations studied [2].
Candidal vaginitis is a generic term used for vaginal
infections caused by Candida species. Candida albicans
is responsible for 90% of vulvovaginal candidiasis; the
remaining 10% corresponds to C. glabrata and C. tropi-
calis [2,3]. No data are available for this distribution in
our setting.
Microscopic examination of vaginal discharge is the
main tool for diagnosis. It allows the diagnosis in most
of the cases. Fungal culture is useful when the mycro-
scopic examination of the swab is negative and patient
refers suggestive symptoms of Candida infection or in
cases of chronic recurrent vulvovaginitis. The culture
is not useful in women who received an anti-fungal
therapy during last week (90% will have a negative cul-
ture) [3]. Common practice is, when symptoms of sus-
picion occur, to take a clinical history, physical
examination and a vaginal swab, and initiating empiri-
cal treatment before microbiological confirmation.
However, symptoms alone do not allow clinicians to
distinguish confidently between the causes of vaginitis.
The sensitivity of the classic symptoms of vulvovaginal
candidiasis (itching, white cheesy discharge) ranges
between 41 and 91% and a specificity between 47 and
73%; this is why the microbiological study is recom-
mended [4].
Vulvovaginal candidiasis is treated with a variety of
anti-fungal drugs, administered oral or topically (vaginal)
[5-9]. In simple or uncomplicated cases there is no dif-
ference in the relative effectiveness (measured as clinical
and mycological cure) of anti-fungals in both ways of
administration (vaginal and oral), including single-dose
regimens, neither between preparations of different time
and dose intervals (level 1 of evidence). Patient prefer-
ences, the response to previous treatment and the cost
should guide our choice [7].
The main purpose of Cochrane’s review (2007), which
included 17 clinical trials, was to assess the relative
effectiveness of anti-fungals imidazol y triazol (both oral
and intravaginal) for the treatment of uncomplicated
vaginal candidiasis. Secondary endpoints evaluated the
cost-effectiveness, safety and patient preference of oral
versus intravaginal anti-fungals. According to this review
no definitive conclusion can be made regarding the rela-
tive safety of oral and intravaginal anti-fungals for
uncomplicated vaginal candidiasis because side effects
data were poorly reported in different studies. It should
be noted that in this review trials involving ketoconazol
due to “its association with serious adverse reactions
and to its limited license” were excluded [8].
Intravaginal anti-fungals present a higher frequency of
topical reactions (eg irritation, burning, itching) than the
ones administered orally, although systemic effects
(headache) are also reported. The oral administration is
associated with a wide range of systemic effects includ-
ing gastrointestinal side effects and headache. The rate
of reported side effects per 100 patients was for each
anti-fungal the follow: 21% for fluconazol, 22% for clo-
trimazol, 23% for itraconazol and 12% for econazol and
miconazol [8].
Ten clinical trials dealt with women’sp r e f e r e n c e
regarding the anti-fungals way of administration, but the
presented data were not sufficient to answer this ques-
tion [10-20]. The Cochrane review’sa u t h o r sc o n c l u d e d
that all studies that dealt with preferences are in favor
of oral treatment (compared to intravaginal or no pre-
ference) with a fluctuation from 43% for women at Van
Heusdenal’s trial [20] to 93% at Timonen’st r i a l[ 1 6 ] .
Nevertheless, inconsistencies associated with the report
of the preferred way of administration limit the use of
such data. According Cochrane review, at the studies
dealing with preferences, patients are inclined to oral
treatment against vaginal between 46% [18] and 93%
[16] of the cases.
We should bear in mind, however, that oral prepara-
tions are generally more expensive than intravaginal
treatments and systemic side effects associated with oral
therapy are likely to be more serious than the intravagi-
nal one [21]. As for clinical implications the authors of
the review suggest that, unless there is a history of
adverse reaction to one of the ways of administration or
contraindications, women who acquire their own treat-
ment should receive full information regarding the char-
acteristics and cost of treatment, allowing them to make
their own decision. If health services are paying the
treatment cost, decision-makers should consider
whether the higher cost of some oral anti-fungals
assume is worth the gain in convenience, if this is the
patient’s preference [8].
According to american statistics between 5% -7% of
women will have recurrent candidal vulvovaginitis
(VVCR), defined as 4 or more microbiologically docu-
mented episodes in a year. In these cases, although
C. glabrata was isolated in a 15% ratio, C. albicans is
still the most common responsible organism [2]. There
are several pathophysiological theories. Some authors
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disproportionate response to small amounts of antigen
of Candida mediated through IgE [2,22]. But there is
controversy about some of the causes that predispose to
vaginal colonization. Other causes described in the med-
ical literature are: increased estrogen levels (pregnancy,
especially the third quarter; high-dose oral contracep-
tives; the luteal phase of menstrual cycle), recent treat-
ment with broad spectrum antibiotics (ampicillin,
tetracyclines and cephalosporins), situations of immuno-
suppression (treatments with corticosteroids, HIV) and
diabetes mellitus with poor control [23,24]. Although
clinical experience highlights a relationship between the
presence of candidal vaginitis and the use of contracep-
tives, this still remains controversial.
Clinical decisions, recommendations, and practice
guidelines must not only attend to the best available evi-
dence, but also to the values and preferences of the
informed patient [25]. Identifying, critically appraising,
and summarizing the evidence were initial areas of focus
for evidence-based medicine (EBM). However, evidence
alone is not sufficient to make clinical decisions [26]. In
2000, the EBM Working Group presented the second
fundamental principle of EBM (the hierarchy of evi-
dence being the first): whatever the evidence, value and
preference judgments are implicit in every clinical deci-
sion. Values and preferences refer not only the patients’
perspectives, beliefs, expectations, and goals for life and
health, but also the processes individuals use to consider
the available options and their relative benefits, harms,
costs, and inconveniences.
In the methodological manuals for the development of
clinical practice guidelines, the incorporation of the
patient’s perspective is considered. In order to achive
this, the following methodological options are proposed:
a review of the literature on the subject from the
patient’s perspective; investigation focused on the per-
spective of patients; and the inclusion of patients in the
process of development and discussion of the draft
guide [27-30]
In order to develop researches that allow to incorpo-
rate patient’s preferences in medical-decisions making,
the different settings of decisions must be considered.
The first field of decision is individual (micro level)
and it should include decisions such as choice of doc-
tor, how to provide information or choice of treat-
ment. The second level (meso) is related to clinical
decision guidelines for patient groups with similar
characteristics and requires the combination of differ-
ent preferences (groups of people with different prefer-
ences). The third level is called macro or social level.
It deals essentially with elections of health programs
and economic aspects and should always be taken into
account [31].
Our research proposal focuses on the micro level of
decision making, studying preferences in individual deci-
sion making. The results can also be used at the meso
level, through their inclusion into clinical practice guide-
lines. Our intention is to answer the pending questions
that the Cochrane review authors highlight at the impli-
cations for research section [8].
The main aim of our study is to describe the prefer-
ences of women and the factors that let them to choose
the type of administration (oral or topical) for the treat-
ment of uncomplicated vulvovaginal candidiasis in pri-
mary health care. Secondary objectives are to determine:
1) the prevalence of different candida species, 2) the
safety of administered treatments, calculated as the
number of topical or systemic adverse reactions, 3) time
of symptom relief and 4) the frequency of recurrent vul-
vovaginal candidiasis (> 4 episodes per year, documen-
ted microbiologically) as well as predisposing factors.
Methods/Design
Design of study
Prospective observational study of one year follow up.
Post-authorization study.
Setting
17 public health centers, Primary Care Health Service of
Madrid (Spain).
Type of participants
Women aged 16 years or over with symptoms of vagini-
tis (see Figure 1).
Criteria of exclusion
1. Pharmacological allergy to any of the proposed
treatments.
2. Women with complicated candidiasis (pregnancy,
symptoms or severe inflammation, no presence of Can-
dida-albicans species, recurrence, poorly controlled dia-
betes mellitus).
3. Treatment with topical or oral antifungals in the
week prior to the consultation.
4. Patients who are away from their homes and do not
intend to reside in the district of the health service in
the following year.
5. Patients were the taking of the swab is not possible.
6. Having had sex without use of barrier methods in
the previous 24 hours.
7. Intravaginal showers in the last 12 hours.
8. Breastfeeding.
9. Use of oral corticosteroids or immunosuppressants
in the last week.
10. HIV.
11. Patients taking oral anticoagulants or
anticonvulsants.
11. Mental illnesses that prevent data collection.
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It was calculated to estimate a proportion, assuming an
expected preference for oral treatment of 43% with an
a l p h ar i s ko f0 . 0 5a n dap r e c i s i o n0 . 4 .T h es a m p l es i z e
was overestimated, considering a 20% loss. The sample
size required is 703.
Sampling technique
Assistant researchers included in the study all patients
who meet the selection criteria during the year-long
recruitment. Patients will be captured in a total of 17
Primary Health Care Centres of the National Health
Service by 21 family physician.
 
12  months
5-8 days
5-8 days
Culture negative for 
Candida or positive for 
other  germs 
Women aged 16 and over with vaginal discharge     
and/or vaginal pruritus  
Candida 
albicans 
Candida 
albicans 
 
YES
NO 
YES 
Informed       
consent 
Inclusion criteria 
Reason for non-
acceptance 
            Anamnesis+vulvar examination+vaginal swab taken 
Important 
symptoms of 
candidal 
 Information about different treatment and 
treatment given according to preferences 
 
 
YES 
NO 
 Assesment regarding clinical recovery  
 Side effects of the drug 
Swab's 
results 
Information about different treatment and 
treatment given according to preferences 
Assesment regarding clinical recovery  
Side effects of the drug 
Assesment for repeated episodes of vulvovaginitis and risk factors  
Exclusion 
End 
Culture negative for 
Candida  or positive 
for other germs 
Swab's 
results 
End 
Figure 1 Trial profile.
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The variable result will be choice of treatment:t y p eo f
drug, oral or intravaginal administration (pessary or
cream), single or multiple doses and reasons for choosing
it. The independent variables, will be: the demographics
(age, nationality, employment status, educational level,
family income per month), data from the history (history
of vaginal candidiasis, previous experience of treatment,
use of vaginal antiseptics), side effects (present side
effects in the first week, treatment discontinuation due to
side effects), time to symptoms disappearance, and etio-
logic (Candida species).
To study the factors associated with recurrent vulvo-
vaginal candidiasis, the variables are: number of episodes
of vaginitis per year (documented microbiologically), the
use of hormonal contraceptives, hormone replacement
therapy, allergic rhinitis, diabetes mellitus, antibiotic
administration in the last week (specifying the type of
antibiotic), use of spermicides, panty or pantyliners,
intravaginal showers, history of childbirth, menstrual
phase and sex.
Data collection
The information will be collected by the patient’so w n
family physician through a personal interview. In
patients who met the inclusion criteria, the physician
will inform the patient of the study’s characteristics and
will ask informed consent. Women who do not agree to
participate will be asked why.
During first visit anamnesis and vulvar inspection will be
carried out, with vaginal swab taking. A cotton swab trans-
port medium will be used, that will be sent to the refer-
ence laboratory within 24 hours, as standard practice. In
women with few symptoms the start of the treatment may
be delayed until the microbiological confirmation.
The doctor will inform the patient about treatment
options (drugs, administration, dosages and costs) and a
treatment will be initiated according to her preference.
The proposed prescription options are the ones recom-
mended in the literature [2,6,9,21]. The information pro-
vided to women has been developed taking into account
the results of a discussion group of women with candi-
dal vaginitis and primary health care physicians working
on different formats and content. The final proposal
includes three cards that provide various options
grouped by: oral/vaginal administration, single dose/
multi dose, side effects and costs.
The second visit will take place in a period between
5-8 days after initiating treatment. Microbiological diagno-
sis will be confirmed. Clinical cure (disappearance of
symptoms) will be assessed as well as possible side effects.
If no treatment was started at the first visit, informa-
tion on treatments will be offered to woman and prefer-
ences will be asked. In these cases, information on side
effects and symptoms disappearance after 7 days will be
gathered by telephone.
Patient will be informed for the necessity of contacting
the doctor at the appearance of new episodes.
The third visit will be arranged after the review of the
clinical history, 12 months later. Whenever is possible,
patient will be given an appointment in order to gather
information; if it is not possible, the consultation will be
carried out by telephone.
For this study an electronic notebook for data collec-
tion was designed.
Type of analysis
Will be described for each of the objectives.
Main objective
Women’s preferences on way of administration will be
described, by calculating proportions with the corre-
sponding confidence intervals. Thereafter, the associa-
tion of each of the independent variables to the
dependent ones will be studied, using as statistical tests
to compare proportions Pearson’s chi-square test or
Fisher’s exact test (when chi-square test conditions of
application are not satisfactory) and to compare means
Student’s t-test or Mann Whitney U nonparametric test.
Afterwards, multivariate analysis will be carried out, in
order to build an explanatory model, where the depen-
dent variable is the chosen way of administration, and
the independent variables, the ones that in the bivariate
analysis were associated with patient’s preference or
such an association is described in the literature.
Secondary objectives
Objective 1 To describe the Candida species responsible
of the clinic
by proportions-calculator with their confidence intervals.
Objective 2 To describe the adverse reactions observed
by using the mean and standard deviation. To compare
the adverse reactions for treatment regarding the way of
administration, Student’s t-test or Mann Whitney U
non-parametric test will be used.
Objective 3 To calculate the average number of days in
the relief of symptoms for each way of administration.
A survival analysis will be carried out applying Cox’s
regression model.
Objective 4 To calculate the frequency of patients with
VVCR criteria. There will be a multivariate analysis,
applying logistic regression: the dependent variable will
be recurrence (VVCR criteria) and the independent vari-
ables the ones that in the bivariate analysis were asso-
ciated with the recurrence of infection or are described
in the literature as risk factors.
Limitations of the study
Patients will be included in the study by their own
family physicians. The implication of a large number of
Del-Cura González et al. BMC Public Health 2011, 11:63
http://www.biomedcentral.com/1471-2458/11/63
Page 5 of 8professionals will increase diagnosis variability (in this
case limited beeing a microbiological diagnosis).
The microbiological study will be carried out by 5
reference laboratories, therefore variability in the meth-
ods of sample analysis might also increase. But then, the
results will reflect what is done usually in everyday-prac-
tice which gives the study feasibility and applicability.
Doctor’s style and his preferences can influence the
way in which different treatment alternatives are offered
to the patient, so bias might be introduced. This will be
minimized by the choice card system of preferences in
which all participant doctors will be trained in a 4 hours
session.
Although we have to contemplate losses in the follow
up process, in primary health care service this is
reduced due to the total accessibility to the public
health system. In order to give answer to our main
objectives, the follow up is of 7 days and it is unlikely
that losses will be important. However, with the purpose
of minimize them, women who do not attend the sched-
uled visit, will be located by telephone and try to recap-
ture them. If she is unable to attend the consultation,
the information on side effects will be gathered by tele-
phone. The losses after a year may be higher but we will
try to reduce them in the same way. Patients consent to
be included in the study and the fact that her own
family physician will make this offer, will limit losses as
it is described in previous studies [32,33]. Although the
ideal design for comparing the safety of various treat-
ments is the clinical trial, post-authorization observa-
tional studies are also of interest, in order to describe
side effects, especially by making use of the information
gathered in usual clinical practice.
Ethical considerations
The study has been approved by the Clinical Research
Ethics Committee of Area 9 of the Primary Care of
Madrid. It has been registered with reference code ICG/
TVC/2008/01 and it has also been authorized by the
Department of Health of the Community of Madrid.
The study will respect the 2008 Helsinki Declaration.
C o n f i d e n t i a l i t ya n da n o n y m i t yo fd a t aw i l lb es t r i c t l y
maintained, according to 15/1999 data protection act,
both in the implementation phase of the project and in
the resulting presentations or publications. Any sus-
pected adverse reaction to treatment will be reported to
the Pharmacovigilance Centre of the Community of
Madrid.
Discussion
Our study aims to provide information about the prefer-
ences of patients and the safety of treatments in order
to help the family physician to take the decision to pre-
scribe or recommend an oral or intavaginal antimycotic.
To make this decision within the health system, beside
efficacy and safety of treatment, costs and patient pre-
ferences, must be also taken into account. These prefer-
ences are mostly studied by the pharmaceutical industry
on their own products, but in populations highly differ-
ent from the Spanish one.
The choice from various medical treatments is not a
purely technical problem. As suggested by some authors,
these elections call to resolve dilemmas that are emotive
and subjective. Situations that are not usual during con-
sultations but are normal when choosing a car or in dif-
ferent personal decision taking. Patients are not
accustomed to these dilemmas in relation to health and
illness and can not make these decisions intuitively. We
need to make these kind of decisions in a structured
way [31].
It is essential that treatments in clinical practice
guidelines should incorporate the results of researches
which main objective is to study the patient’s prefer-
ences. In recent years, all agencies that develop guide-
lines are preparing methodological proposals in this
regard [27,29]. Our proposed methodology has a quanti-
tative approach but it could be expanded in a second
phase also with a qualitative approach that explore
other areas related to patient preferences, and allows to
benefit from both methodologies [34].
The fact that the aim of the study was the safety
of treatments had determined its characteristics. Initially
we designed a prospective observational study that would
reflect the preferences of patients, but adverse effects of
treatments was a question still unanswered. By including
such an aspect, our study became a post-authorization
study with medication, although all treatments offered
are licensed drugs, according the legislation of the Com-
munity of Madrid, with a longstanding experience.
From the clinical point of view, the study incorporates
some new aspects to measure therapeutic response. In
most drug-efficacy studies, clinical cure is assessed after
7 days [12,17,18,20], and after 5-16 days [11,35,36] but
we think it is interesting to evaluate the time for the
relief of symptoms, since there is disagreement about
whether the symptoms were relieved earlier with oral or
topical drugs. In this way, Seidman LS [37] reported
that the relief of symptoms is 24 hours with topics and
46 hours with orals. However, another study [11]
reports that time is shorter with oral fluconazole (1 day)
in comparison to topical chlotrimazole (2 days).
On the other hand, risk factors associated with recur-
rent vulvovaginal candidiasis still remain controversial
[23] and an approach from a prospective study like the
one proposed here can help answering this question.
As said before vaginitis is the most frequent gynecolo-
gical cause of consultation in primary health care and
many women throughout their life will consult their
Del-Cura González et al. BMC Public Health 2011, 11:63
http://www.biomedcentral.com/1471-2458/11/63
Page 6 of 8doctors for this reason. The different treatment options
have all limited side effects, only exceptionally severe
ones, and cost rates are affordable to the majority of the
population.
Probably all agree on the importance of incorporating
preferences in dilemmas with a high emotional charge
(cancer treatments, surgeries, etc). But we can not
ignore the fact that although family physicians in many
cases have to inform the patient for serious health pro-
blems or for processes that limit their quality of life,
there are many more everyday clinical decisions for
minor health problems that are very important.
It is important to raise research questions that can
help us to make progress in the incorporation of patient
preferences to the decision-making, so we can contri-
bute to the change of the doctor-patient relationship. JL
Pinto y cols [31] quote professor Alan Williams in his
ingenious play on words where “the patient is to give
the doctor all the information the physician deems
necessary, so the doctor can make a decision and the
patient should do it once the doctor has taken the deci-
sion” has changed to a relationship where “the physician
is to give the patient all the information the patient
deems necessary for the patient to take a decision, and
the physician should do it once the patient has taken
the decision”.
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